BAYER AG |
Markt geschlossen -
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
| 110,2 PLN | -3,01 % |
|
-0,98 % | -23,49 % |
Kurzporträt
- Produkte für die Landwirtschaft (48,8%): Herbizide, Fungizide, Insektizide usw.;
- pharmazeutische Produkte (38%): zur Vorbeugung gegen und zur Behandlung von Herz- und Kreislauferkrankungen sowie von Erkrankungen der Atemwege, Diabetes, Störungen des Nervensystems usw.;
- OTC-Produkte und Nahrungsergänzungsprodukte (12,7%);
- sonstige (0,5%).
Geographisch gesehen verteilt sich der Umsatz wie folgt: Deutschland (5,1%), Schweiz (1,2%), Europa / Naher Osten / Afrika (23,2%), Vereinigte Staaten (30,6%), Nordamerika (3,5%), China (7,6%), Asien / Pazifik (10%) , Brasilien (10,4%) und Lateinamerika (8,4%).
Umsatz nach Geschäftsbereich
| EUR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
Crop Science
48,8
%
| 25 169 | 49,6 % | 23 270 | 48,8 % | -7,54 % |
Pharmaceuticals
38,0
%
| 19 252 | 37,9 % | 18 081 | 38,0 % | -6,08 % |
Consumer Health
12,7
%
| 6 080 | 12,0 % | 6 027 | 12,7 % | -0,87 % |
All Other
0,5
%
| 217 | 0,4 % | 238 | 0,5 % | +9,68 % |
Enabling Functions and Consolidation
0,0
%
| 21 | 0,0 % | 21 | 0,0 % | 0,00 % |
Umsatz je Region
| EUR in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
United States
30,6
%
| 15 685 | 30,9 % | 14 587 | 30,6 % | -7,00 % |
Europe/Middle East/Africa
23,2
%
| 11 352 | 22,4 % | 11 071 | 23,2 % | -2,48 % |
Brazil
10,4
%
| 5 322 | 10,5 % | 4 967 | 10,4 % | -6,67 % |
Asia/Pacific
10,0
%
| 5 192 | 10,2 % | 4 745 | 10,0 % | -8,61 % |
Latin America
8,3
%
| 3 966 | 7,8 % | 3 961 | 8,3 % | -0,13 % |
China
7,6
%
| 4 259 | 8,4 % | 3 624 | 7,6 % | -14,91 % |
Germany
5,1
%
| 2 477 | 4,9 % | 2 448 | 5,1 % | -1,17 % |
North America
3,5
%
| 1 886 | 3,7 % | 1 667 | 3,5 % | -11,61 % |
Switzerland
1,2
%
| 600 | 1,2 % | 567 | 1,2 % | -5,50 % |
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 57 | 01.04.23 |
| Director of Finance/CFO | 55 | 26.04.18 | |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 55 | 01.04.20 |
Christian Rommel
CTO | Chief Tech/Sci/R&D Officer | 57 | 01.02.21 |
| - | - | ||
Heike Prinz
PRN | Corporate Officer/Principal | - | 01.09.23 |
Itziar Canamasas
PRN | Corporate Officer/Principal | 50 | - |
Ruzha Draganova
PRN | Corporate Officer/Principal | - | 01.01.15 |
Rodrigo Santos
PRN | Corporate Officer/Principal | 51 | - |
Miriam Holstein
PRN | Corporate Officer/Principal | - | 01.01.22 |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
Colleen Goggins
BRD | Director/Board Member | 68 | 01.04.17 |
Alberto Weisser
BRD | Director/Board Member | 68 | 01.04.21 |
Paul Achleitner
BRD | Director/Board Member | 67 | 01.04.02 |
Ertharin Cousin
BRD | Director/Board Member | 67 | 01.10.19 |
| Director/Board Member | 66 | 28.04.20 | |
Heike Hausfeld
BRD | Director/Board Member | 58 | 01.01.94 |
André van Broich
BRD | Director/Board Member | 54 | 01.04.12 |
Frank Löllgen
BRD | Director/Board Member | 63 | 01.11.15 |
| Director/Board Member | 64 | 01.04.22 | |
Andrea Sacher
BRD | Director/Board Member | 43 | 01.09.20 |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 1 | 982 424 082 | 982 167 123 ( 99,97 %) | 0 | 99,97 % |
Unternehmensbesitz
| Name | Aktien | % | Bewertung |
|---|---|---|---|
BAYER CROPSCIENCE LIMITED 71,43% | 32 102 999 | 71,43% | 2 597 595 223 $ |
CENTURY THERAPEUTICS, INC. 15,00% | 12 675 838 | 15,00% | 32 323 387 $ |
METAGENOMI, INC. 10,81% | 4 050 997 | 10,81% | 16 528 068 $ |
BOUNDLESS BIO, INC. 7,26% | 1 615 201 | 7,26% | 6 250 828 $ |
SENTI BIOSCIENCES, INC. 12,85% | 5 878 488 | 12,85% | 1 622 463 $ |
| 1 490 625 | 0,38% | 383 195 $ | |
AZITRA, INC. 4,54% | 1 307 401 | 4,54% | 120 281 $ |
Unternehmenskontakt
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
Bayer Corp.
 Bayer Corp. Pharmaceuticals: MajorHealth Technology Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ. |
Pharmaceuticals: Major
|
Schering Berlin, Inc.
 Schering Berlin, Inc. Medical SpecialtiesHealth Technology Part of Bayer AG, Schering Berlin, Inc. is a company that manufactures pharmaceuticals and diagnostic substances. The company is based in Whippany, NJ. |
Medical Specialties
|
Wholesale Distributors
| |
Bayer Healthcare LLC
 Bayer Healthcare LLC Pharmaceuticals: MajorHealth Technology Bayer Healthcare LLC provides healthcare and pharmaceutical medicines. It also provides researching, developing, manufacturing and marketing services for the prevention, diagnosis and treatment of diseases. The company is headquartered in Whippany, NJ. |
Pharmaceuticals: Major
|
Seminis Vegetable Seeds, Inc.
 Seminis Vegetable Seeds, Inc. Agricultural Commodities/MillingProcess Industries Seminis Vegetable Seeds, Inc. engages in plant breeding research and development services. It develops types of vegetables, which are marketed to commercial vegetable growers, dealers, distributors, and wholesalers. The firm’s products include Fresh Market, Home Garden, Processor, Performance Series Sweet Corn, SummerSlice Watermelons and Pepper X10R and Technology. The company was founded in 1865 and is headquartered in St. Louis, MO. |
Agricultural Commodities/Milling
|
Bayer CropScience Ltd. (United Kingdom)
 Bayer CropScience Ltd. (United Kingdom) Chemicals: AgriculturalProcess Industries Bayer CropScience Ltd. manufactures and markets crop protection products. It offers fungicides, herbicides, insecticides, rodenticides and seeds. The firm also engages in the breeding, development, production, and marketing of hybrid seeds. The company is headquartered in Cambridge, the United Kingdom. |
Chemicals: Agricultural
|
Asklepios BioPharmaceutical, Inc.
 Asklepios BioPharmaceutical, Inc. BiotechnologyHealth Technology Asklepios BioPharmaceutical, Inc. operates as a gene therapy-based company. It engages in capsid development, scaled manufacturing, and a portfolio of therapeutic programs. The company was founded by Richard Jude Samulski, Xiao Xiao, and Sheila A. Mikhail in 2001 and is headquartered in Durham, NC. |
Biotechnology
|
Intendis GmbH
 Intendis GmbH Pharmaceuticals: MajorHealth Technology Intendis GmbH specializes in dermatological drugs. Its products are to treat acne, rosacea, eczema, psoriasis, and fungal infections. The company operates in Austria, Brazil, France, Germany, Italy, Japan, Mexico, Poland, Portugal, Russia, Spain, Turkey, and the USA. It was founded in 2005 and is headquartered in Berlin, Germany. |
Pharmaceuticals: Major
|
Chemicals: Agricultural
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
| % 1. Jan. | Kap. | |
|---|---|---|
| +61,53 % | 856 Mrd. | |
| +38,95 % | 631 Mrd. | |
| -3,66 % | 359 Mrd. | |
| +15,06 % | 325 Mrd. | |
| +9,18 % | 297 Mrd. | |
| +5,89 % | 234 Mrd. | |
| +16,53 % | 226 Mrd. | |
| +15,67 % | 177 Mrd. | |
| +2,47 % | 165 Mrd. |
- Börse
- Aktien
- BAY001 Aktie
- BAY001 Aktie
- Unternehmen Bayer AG
